Review top news and interview highlights from the week ending May 27, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
NeoCart was originally developed by the company Histogenics.
A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.
The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.
The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
The positive opinion was based on findings from studies conducted in Taiwan.